Oncology Research Excellence

Chemotherapy Research and Practice

Advancing Cancer Treatment Through Innovation

The International Journal of Chemotherapy Research and Practice publishes groundbreaking research in anticancer drug development, drug resistance mechanisms, novel therapeutic strategies, supportive care interventions, and precision oncology advancing our understanding of cancer pharmacology and improving patient outcomes worldwide through evidence-based chemotherapy optimization.

Join a dedicated global community of medical oncologists, pharmaceutical scientists, cancer biologists, clinical researchers, and supportive care specialists pioneering new chemotherapy regimens, targeted therapies, and combination strategies transforming cancer treatment paradigms and improving survival rates for diverse malignancies.

Bridging Discovery and Clinical Application

The International Journal of Chemotherapy Research and Practice serves as the premier platform for disseminating cutting-edge research advancing cancer pharmacology from bench to bedside. Our rigorous peer review by medical oncology and pharmaceutical science experts ensures the highest scientific standards while accelerating knowledge translation improving chemotherapy efficacy and tolerability for patients globally.

Comprehensive Research Scope

We publish comprehensive investigations spanning anticancer drug discovery including natural product screening and rational drug design, pharmacokinetic and pharmacodynamic studies optimizing dosing schedules, drug resistance research examining efflux pumps and DNA repair upregulation, combination therapy studies identifying synergistic drug interactions, biomarker development predicting treatment response, clinical trials evaluating new agents and regimens, and supportive care interventions managing chemotherapy-induced adverse effects including nausea peripheral neuropathy and myelosuppression improving patient quality of life during treatment.

Editorial Excellence

Our international editorial board comprises medical oncologists with extensive chemotherapy administration experience across solid and hematologic malignancies, pharmaceutical scientists expert in drug metabolism and formulation, cancer biologists investigating resistance mechanisms, clinical pharmacologists optimizing dosing strategies, and supportive care specialists managing treatment toxicities ensuring comprehensive expertise across chemotherapy research domains and commitment to advancing cancer care through open access scholarly communication reaching oncology professionals worldwide.

Research Focus Areas

Drug Development Pipeline

Research on anticancer agent discovery through screening natural products and synthetic compounds for cytotoxic activity, structure-activity relationship studies optimizing drug potency and selectivity, preclinical efficacy testing in cell culture and animal models assessing tumor growth inhibition, pharmacokinetic profiling determining absorption distribution metabolism and excretion, toxicology studies identifying dose-limiting side effects, phase I dose-escalation trials establishing maximum tolerated dose, phase II efficacy trials assessing response rates in specific cancers, and phase III randomized comparisons against standard chemotherapy determining survival benefits guiding regulatory approval and clinical adoption advancing cancer treatment options.

Drug Resistance Mechanisms

Investigations of multidrug resistance through ATP-binding cassette transporter overexpression pumping chemotherapy out of cancer cells, DNA repair pathway upregulation including nucleotide excision repair and mismatch repair reducing platinum and alkylating agent cytotoxicity, apoptosis resistance via BCL-2 family protein expression preventing programmed cell death, cell cycle checkpoint alterations allowing continued proliferation despite DNA damage, cancer stem cell populations exhibiting intrinsic chemoresistance, tumor microenvironment protection through stromal cell support and hypoxia-induced drug resistance, and resistance reversal strategies including efflux pump inhibitors and combination therapies overcoming resistance mechanisms improving treatment efficacy for refractory cancers.

Targeted Therapy Integration

Studies on combining conventional cytotoxic chemotherapy with targeted molecular agents including tyrosine kinase inhibitors blocking growth factor receptor signaling, monoclonal antibodies targeting tumor antigens for antibody-dependent cytotoxicity, angiogenesis inhibitors disrupting tumor blood supply, immune checkpoint inhibitors enhancing T cell-mediated tumor killing, PARP inhibitors inducing synthetic lethality in BRCA-mutated cancers, CDK4/6 inhibitors arresting cell cycle progression, and mTOR inhibitors blocking proliferation pathways demonstrating improved response rates and progression-free survival compared to chemotherapy alone in molecularly selected patient populations advancing precision oncology treatment strategies.

Supportive Care Optimization

Publications addressing chemotherapy-induced nausea and vomiting prevention through 5-HT3 receptor antagonists and NK1 antagonists, neutropenic fever risk reduction via granulocyte colony-stimulating factors enabling dose-dense chemotherapy regimens, peripheral neuropathy management challenging with taxanes and platinum agents, cardiotoxicity prevention during anthracycline therapy through dexrazoxane cytoprotection, mucositis treatment supporting oral hygiene and pain management, fatigue interventions including exercise programs and psychosocial support, cognitive dysfunction assessment documenting chemobrain effects, and fertility preservation strategies including oocyte and sperm banking before gonadotoxic treatment improving quality of life and treatment tolerability enabling optimal chemotherapy delivery.

Precision Dosing Strategies

Research on therapeutic drug monitoring measuring plasma drug concentrations guiding dose adjustments, pharmacogenomic testing identifying genetic variants affecting drug metabolism through CYP450 enzymes and drug transporters predicting toxicity risk, body surface area-based dosing limitations and alternative strategies including fixed dosing or AUC-targeted dosing, chronotherapy optimizing administration timing based on circadian rhythms, continuous infusion versus bolus administration comparing pharmacodynamics, dose-dense scheduling reducing recurrence risk, maintenance chemotherapy extending progression-free survival, and personalized dosing algorithms integrating clinical and genomic factors optimizing individual patient outcomes balancing efficacy against toxicity achieving therapeutic goals.

Global Access and Equity

Studies addressing essential chemotherapy availability in low-resource settings where access to targeted therapies remains limited, generic drug development reducing treatment costs, simplified regimens appropriate for resource-constrained healthcare systems, oral chemotherapy formulations enabling outpatient administration reducing hospitalization burden, telemedicine monitoring managing treatment toxicities remotely, biosimilar development for expensive monoclonal antibodies, compounding pharmacy protocols ensuring drug stability and sterility, patent reform facilitating affordable generic production, and international collaboration advancing global cancer control ensuring all patients worldwide benefit from chemotherapy advances regardless of geographic or economic status reducing global cancer mortality disparities.

Membership Investment

Select the tier supporting your chemotherapy research dissemination goals and publication frequency requirements.

Individual

Oncologist

$2,100

12 months

1 Full Article

Best Value

Individual

Oncologist Plus

$3,800

24 months

2 Full Articles

Institutional

Cancer Center

$12,500

12 months

25 Article Cap

Membership Advantages

💉

Expert Oncology Review

Manuscripts receive evaluation by board-certified medical oncologists and pharmaceutical scientists with deep expertise in chemotherapy mechanisms toxicities and clinical applications ensuring rigorous peer review and constructive feedback improving manuscript quality and advancing cancer pharmacology knowledge through high-impact publications reaching global oncology communities.

⚡

Accelerated Publication

Members receive priority editorial screening within seventy-two hours, expedited peer review averaging four weeks for initial decisions, and fast-track publication within three weeks following acceptance for practice-changing research requiring immediate clinical implementation enabling rapid dissemination of breakthrough chemotherapy discoveries improving patient outcomes globally.

🎓

Clinical Translation Focus

Our journal emphasizes translational research bridging laboratory drug discovery with bedside cancer treatment applications ensuring published studies address clinically relevant questions informing oncology practice guideline development and regulatory decision-making advancing evidence-based chemotherapy optimization improving survival and quality of life for cancer patients worldwide.

🌐

Global Research Network

Connect with leading academic cancer centers, pharmaceutical companies developing novel anticancer agents, biotechnology firms pioneering targeted therapies, clinical research organizations conducting multinational trials, and international oncology societies implementing cancer control programs facilitating collaborative research advancing chemotherapy science from fundamental pharmacology through clinical validation and global implementation.

Transforming Cancer Care Worldwide

The IJCP research community encompasses leading academic oncology departments investigating chemotherapy pharmacology and resistance mechanisms, comprehensive cancer centers administering multimodal treatment regimens, pharmaceutical companies developing next-generation cytotoxic and targeted agents, biotechnology firms pioneering antibody-drug conjugates and immunotherapies, clinical research networks conducting international trials establishing new treatment standards, patient advocacy organizations supporting research funding and survivorship programs, and regulatory agencies reviewing safety and efficacy data. Member collaboration advances chemotherapy science from fundamental cancer cell biology through drug development clinical validation and global guideline implementation improving cancer survival rates and quality of life for millions of patients worldwide through evidence-based treatment optimization personalized medicine approaches and supportive care interventions managing treatment toxicities enabling delivery of curative or life-prolonging chemotherapy benefiting society globally.

Membership Questions?

Contact our editorial team for assistance with membership and publication inquiries.

[email protected]

Publish Your Chemotherapy Research

Submit your cancer pharmacology and chemotherapy research for expert peer review and immediate global open access distribution advancing oncology treatment and improving patient outcomes worldwide.

Submit Manuscript Quick Form

International Journal of Chemotherapy Research and Practice

International Journal of Chemotherapy Research and Practice – Membership